A Randomized Double Blinded Two-way Crossover Single-dose Pharmacokinetics and Pharmacodynamics Study of GP-40081 (LLC "GEROPHARM", Russia) Versus NovoMix® 30 Penfill® (Novo Nordisk) in Healthy Subjects Using the Euglycemic Clamp Technique
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 34
- 试验地点
- 2
- 主要终点
- AUC(0-t)
研究概览
简要总结
Pharmacokinetics and pharmacodynamics study of 2 formulations of biphasic insulin aspart 30 (GP-40081 GEROPHARM vers. NovoMix® 30 Penfill® Novo Nordisk)
详细描述
A randomized double blinded two-way crossover single-dose pharmacokinetics and pharmacodynamics study of GP-40081 (LLC "GEROPHARM", Russia) versus NovoMix® 30 Penfill® (Novo Nordisk) in normal healthy subjects using the euglycemic clamp technique
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Single (Outcomes Assessor)
盲法说明
This study was blinded for Sponsor, investigators and analytical laboratory
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Signed informed consent.
- •Caucasian males having a confirmed healthy diagnosis as per data of standard clinical, laboratory, and instrumental examination methods.
- •Age of 18-45 (both incl.).
- •Body mass index equal to 18.5-30.0 kg/m2, body weight equal to 60.0-100.0 kg (both incl.).
- •Volunteers' consent to all restrictions imposed during the study, including adequate methods of contraception.
- •Russian citizenship.
排除标准
- •Weighed allergic anamnesis.
- •Increased sensitivity in the history of heparin, insulin or any of the excipients of the study drugs.
- •Any acute and chronic diseases (for 4 weeks before screening) incl.:
- •of the cardiovascular system, bronchopulmonary, neuroendocrine systems, as well as diseases of the gastrointestinal tract, liver, kidneys, blood.
- •positive tests: hepatitis B (Ag), hepatitis C (Ab), HIV (Ab), syphilis (Ab).
- •Deviations in basic vital signs: heart rate (60-89), systolic blood pressure (90-139 mm Hg), the diastolic blood pressure (60-89 mm Hg), respiratory rate (12-20), body temperature (35.7-37.2 C).
- •Abnormalities of the ECG from the norms.
- •Episodes of hypoglycemia in the anamnesis; the presence in the family history of cases of a verified diagnosis of diabetes mellitus in the immediate family.
- •Fasting plasma glucose> 6.1 mmol / L.
- •HbA1C> 6% (screening).
- •Oral glucose tolerance test - blood glucose level ≥ 7.8 mmol / l (2 hours after loading with glucose).
- •Deep vein thrombosis of lower extremities in a history of life or in a family history.
- •Any diet (vegetarian, etc.), extreme physical exercise, night shift work.
- •Subjects who have taken any drugs known effects on hemodynamics or to induce or inhibit hepatic drug metabolism within 2 months prior to screening.
- •Taking medications, phytopreparations, biologically active supplements less than 14 days before screening.
- •History of significant drugs abuse conditions for 3 years prior to screening.
- •Significant blood loss (450 mL or more) less than 3 months before the screening.
- •Recovery after surgery process; scheduled surgery.
- •Mental, physical and other reasons that do not allow to adequately assess their behavior and properly fulfill the conditions of the research protocol, including psychiatric disorders.
- •A positive test for the content of drugs in the urine (screening).
- •Positive test for alcohol content in the exhaled air.
- •Receiving more than 10 units. alcohol per week (1 unit of alcohol is equivalent to 0.5 liters of beer, 200 ml of wine or 50 ml of strong alcohol) or anamnestic information about alcoholism.
- •Nicotine dependence (use of tobacco less than 6 months before the start of screening).
- •Participation in a clinical trial of any medications less than 3 months or 5 half-lives before the IP administration.
- •Any conditions that make it difficult, according to the informed opinion of the investigating physician, that volunteer participation in studies.
研究组 & 干预措施
GP-40081
Single subcutaneous administration of GP-40081 in dose 0.4 IU / kg
干预措施: GP-40081 (Drug)
NovoMix® 30 Penfill®
Single subcutaneous administration of NovoMix® 30 Penfill® in dose 0.4 IU / kg
干预措施: NovoMix® 30 Penfill® (Drug)
结局指标
主要结局
AUC(0-t)
时间窗: -60, -30, 0 minutes (pre-dose) and 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 180, 210, 240, 270, 300, 360, 420, 480, 600, 720, 960, 1200 and 1440 minutes post-dose
Pharmacokinetics of insulin aspart by Assessment of Area Under the Curve From Time Zero Extrapolated to "t" (AUC(0-t))
Cmax
时间窗: -60, -30, 0 minutes (pre-dose) and 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 180, 210, 240, 270, 300, 360, 420, 480, 600, 720, 960, 1200 and 1440 minutes post-dose
Pharmacokinetics of insulin aspart by Assessment of Observed Maximum Plasma Concentration (Cmax)
次要结局
未报告次要终点